The article emphasizes the diagnostic criteria for Alzheimer’s Disease (AD), noting that an abnormal Core 1 biomarker is sufficient for diagnosis. Key biomarkers include amyloid PET imaging, cerebrospinal fluid markers, and specific plasma biomarkers like phosphorylated tau 217. Additionally, it highlights that even unimpaired individuals with abnormal biomarker results may be at risk for developing symptoms associated with AD, indicating the importance of early detection and monitoring in at-risk populations.
The diagnostic criteria state that 'an abnormal Core 1 biomarker is sufficient to establish a diagnosis of AD.' Those biomarkers include amyloid PET, approved cerebrospinal fluid biomarkers, and plasma biomarkers (such as phosphorylated tau 217).
'Unimpaired individuals with abnormal biomarker test results are at risk for symptoms due to AD,' the criteria authors wrote.
Collection
[
|
...
]